Persistent Epstein-Barr virus (EBV) infection is primarily controlled by HLA class I-restricted memory cytotoxic T-cell (CTL) responses which can be reactivated in vitro by stimulation of peripheral blood lymphocytes with autologous lymphoblastoid cell lines. During an investigation of a donor infected by both type A and type B EBV, CTL specific for type B EBV were isolated. The CTL were found to recognize an epitope encoded by the EBNA-6B gene. The minimal epitope sequence was identified as QNGALAINTF, corresponding to residues 213 to 222 in the EBNA-6B protein, and presentation of this epitope was shown to be via HLA B62 (B15). This is the first report of the characterization of an epitope that is EBV type B specific. CTL recognizing sequences common to type A and type B EBV were identified as well. A cross-reactive epitope recognized by these CTL was encoded within the EBNA-6 gene of both type A and type B. This minimal sequence for this epitope was LLDFVRFMGV (residues 284 to 293 in both types), and the epitope was restricted through HLA A*0201. This second epitope sequence overlaps with a published EBV B44-restricted epitope (EENLLDFVRF). The implications of these findings are discussed with respect to the design and efficacy of epitope-based vaccines.
Epstein-Barr virus (EBV) is a gamma herpesvirus which establishes a latent lifelong infection in the host following acute infection (13, 14) . While primary infection generally occurs in childhood without significant morbidity, adolescents and young adults may present with the symptoms of acute infectious mononucleosis. The main feature of infectious mononucleosis (IM) is a self-limiting lymphoproliferation involving both T and B cells accompanied by clinical symptoms such as fever and lymphadenopathy (44, 45) .
Evidence for latent EBV infection includes the observation that spontaneous lymphoblastoid cell lines (LCLs) which express EBV-encoded latent proteins can be regularly established from healthy immune individuals after explantation of either lymph node tissue (29) or fractionated B lymphocytes (50) . Although latent EBV infection is usually asymptomatic, sequential studies have established that recrudescence of viral replication in the oral cavity may result in release of infectious virus (50) . The exact site of persistence of the virus is uncertain, but the available evidence suggests that small lymphocytes in the circulation harbor the virus in a nonproductive episomal state (20) . Accordingly, in asymptomatic donors, EBV DNA is detectable by sensitive PCR analysis in peripheral blood lymphocytes (PBL) expressing the B-cell marker CD19 (24, 47) .
Two types of EBV (types A and B or types 1 and 2) are distinguishable primarily on the basis of variation in the DNA and protein sequences of the latent EBV-associated nuclear antigens (referred to here as EBNA-2A, -3A, -4A, and -6A from the type A virus and EBNA-2B, -3B, -4B, and -6B from the type B virus) (8, 38, 40) . Sequencing of the prototypical isolates of type A and type B EBV (B95-8 and Ag-876, respectively) in these regions revealed 53% amino acid homology between EBNA-2A and EBNA-2B (8) and 72 to 84% homology between EBNA-3A and -3B, EBNA-4A and -4B, and EBNA-6A and -6B (38) . Strain variation due to other DNA alterations or deletions as well as these A-B type differences have been defined at the protein (11) and the DNA (21, 22) level and recombination between multiple infecting strains was found to occur frequently in oral hairy leukoplakia lesions (48) . These variations offer an alternative means of categorizing EBV isolates, but the primary distinction of type A and type B is still useful. Type A EBV is more readily isolated from healthy donors; type B EBV infections or dual infections with both type A and type B have proven easier to detect in immunosuppressed or human immunodeficiency virus-infected individuals (2, 39, 43) . A higher incidence of type B infection in some studies led to the suggestion that type B or dual infections are, in fact, relatively common and that resident type B virus levels increase during immunosuppression (2, 18, 43) .
It appears that latent EBV infection is primarily controlled by HLA class I-restricted memory cytotoxic T-cell (CTL) responses (reviewed in reference 16). These CTL responses can be reactivated in vitro by stimulating lymphocytes from seropositive individuals with autologous LCLs which express and present major histocompatibility complex class I-and class II-restricted epitopes at the cell surface. Several of these epitopes have been identified using target cells infected by recombinant vaccinia virus constructs (15, 17, 27, 28) . Epitopes specific for type A EBV as well as cross-reactive epitopes encoded by both type A and B EBV have been defined previously (16) , but no epitopes specific for type B EBV have been reported thus far. In the present study, the response of a donor exposed to both type A and type B EBV was investigated and an epitope specific for type B EBV as well as a new crossreactive epitope were identified.
MATERIALS AND METHODS
Lymphocyte donor. A 17-year-old individual (patient 1) who initially presented with clinical and pathological (EBV immunoglobulin M positive) symptoms of acute infectious mononucleosis was the subject of this study. Blood specimens were obtained from this donor 18 months following primary infection, by which time serology revealed the donor to be EBV immunoglobulin M negative, antiviral capsid antigen positive, and anti-EBNA positive. PCR analysis revealed the presence of both type A and type B EBV in blood from donor patient 1. The presence of both virus types was supported by the observations that both type A and type B spontaneous cell lines grew out (although only the former, EW-spon, was established in long-term culture), and regression analysis (26) indicated that the donor had memory CTL activity to both virus types (data not shown).
Virus typing and detection. EBNA-2A and -2B primers were used in PCR as previously described (18) to distinguish between type A and type B EBV in DNA extracted from PBL.
Vaccinia virus constructs. Recombinant vaccinia virus constructs, encoding EBNA-1, -2B, -4A, and -6A, the latent membrane proteins LMP1 and LMP2, the lytic antigens BHRF1 and BZLF1, and the control vacc-TK Ϫ , have already been described (17, 19, 28) . Vacc-EBNA-3B and vacc-EBNA-6B (i.e., vaccinia virus constructs encoding the type B sequences of EBNA-3 and EBNA-6, respectively) were constructed from an EBV genomic library derived from purified viral genomes of the prototype type B strain Ag-876 (42) . The viral DNA was digested with HindIII and ligated into the -ZAP cloning system (Integrated Sciences).
An 11.07-kbp HindIIIE fragment encoding the EBNA-3B, -4B, and -6B open reading frames (ORFs) was subcloned into the vector pUC19. A 2.6-kbp BamHI-CEIII (Klenow-treated) fragment within the region containing the BERF1 ORF of EBNA-3B (38) was isolated and ligated into a BamHI-HindII digest of pBCB07. This vaccinia virus vector drives recombinant gene expression by the 7.5K vaccinia virus promoter (1) . The EBNA-3B sequence encoded in the transfer plasmid was inserted into the TK gene of vaccinia virus by transfection and homologous recombination as described previously (1) . A 4-kbp Eco47III-HindIII fragment within the EBV HindIIIE region containing the BERF4 ORF of EBNA-6B was isolated and ligated into a HindII-HindIII digest of pBCB07. This was subsequently processed as for EBNA-3B. Integrity of the vacc-EBNA-3B and -6B constructs was confirmed both by immunoblotting and DNA sequencing (data not shown). The EBNA-3B construct encompassed the whole of the EBNA-3B sequence (amino acids 1 to 925 [38] ), and the EBNA-6B construct encompassed the whole EBNA-6B sequence, excluding the first exon (amino acids 100 to 1069 [38] ).
Establishment of cell cultures. (i) B-cell cultures.
LCLs were established from patient 1 by exogenous transformation of PBL with QIMR-WIL virus (type A [31] ) and Ag-876 virus (type B). These LCLs were designated EW-Wil and EW Ag-876. Spontaneous LCLs (i.e., autologous LCLs infected with the donor's endogenous virus strain and designated EW-spon) were established in the presence of cyclosporin (34) . LCLs from other donors were transformed by QIMR-WIL or IARC-BL74 virus (25) (type A isolates) or by Ag-876 or QIMR-GOR virus (30) (type B isolates). Other lines used in this study include Burkitt lymphoma (BL) cell lines (Chep and Mutu) and the spontaneous line QIMR-WW2-LCL (12, 35, 36) . B-cell lines were maintained in RPMI 1640 with 10 to 20% fetal calf serum (FCS).
(ii) T-cell cultures. Unfractionated PBL were separated on Ficoll-Paque (Pharmacia, Uppsala, Sweden) and stimulated by incubation with gamma-irradiated (8,000 rads) autologous LCLs (either type A LCL, EW-Wil, or type B LCL, EW-Ag-876; 2 ϫ 10 6 cells per well in 2 ml of growth medium without recombinant interleukin-2, responder-stimulator ratio, 50:1) (23). After 3 days, the cultures were cloned in agarose (SeaPlaque; FMC Corp, Rockland, Maine) and the colonies were harvested 3 to 5 days later. Once established, the T cells were maintained in T-cell growth medium (RPMI 1640 supplemented with 15% FCS, 30% MLA-144 supernatant [TIB-201; American Type Culture Collection, Rockville, Md.], and recombinant interleukin 2, 20 U/ml) (37, 49) . Since the clonal nature of the T cells was not established, they are referred to in the text as cultures rather than clones. The cultures were routinely maintained in either 24-well plates or tissue culture flasks and restimulated twice weekly with gammairradiated (8,000 rads) autologous LCLs.
Bulk T-cell cultures were subcultured and maintained after 3 to 4 days, as for T-cell colonies. Phytohemagglutinin (PHA) blasts were generated by stimulation of PBL with PHA (CSL, Melbourne, Australia) and subcultured after 4 days in T-cell growth medium. Cultures were regularly screened for mycoplasma contamination and were consistently negative. Natural killer (NK) target line K562 was used in CTL assays.
Fluorescence-activated cell sorter (FACS) analysis. Three-color cytofluorographic analysis of T-cell cultures was performed by means of direct immunofluorescence using labelled monoclonal antibodies specific for CD3 (tricolor conjugated), CD4 (fluorescein conjugated), and CD8 (phycoerythrin conjugated) (Becton Dickinson, San Jose, Calif.). The labelled cells were analyzed on a FACScan (Becton Dickinson lysis II software).
Cytotoxicity assays. T cells were assayed in modified 5-h 51 Cr release assays (25) . Briefly, target cells were labelled for 1 h with 0.5 to 1.0 C of 51 Cr, washed, and resuspended at 10 5 cells per ml. Target cells (50 l) were incubated with an equal volume of effectors (effector-target or E-T ratio, generally 10:1) in 96-well V-bottomed microtiter plates, centrifuged, and incubated at 37ЊC for 5 h. After centrifuging again, 25 l of supernatant was harvested and dried onto 96-well solid scintillation microtiter plates before the radioactivity was counted in a Topcount Microplate Scintillation Counter (Packard Instrument Company, Meridan, Conn.).
For determination of antigenic specificity, target cells were infected with vaccinia virus constructs (multiplicity of infection, approximately 10:1) and labelled with 51 Cr by a modification of the previously described procedure (15) . Infection and labelling occurred simultaneously for 2.5 h before the cells were washed and used in CTL assays. In some instances target cells were pretreated in V-wells with monoclonal antibodies to HLA class I (W6/32) or class II (L243) for 30 min at room temperature before effector cells were added.
Limiting dilution cultures. Limiting dilution cultures were established by distributing PBL in 24 replicates at 2 ϫ 10 4 cells per well in 96-well round-bottomed microtiter plates. Doubling dilutions were made to a final concentration of 1.6 ϫ 10 2 cells per well. Approximately 10 4 gamma-irradiated (8,000 rads) autologous type B (EW-Ag-876) LCLs were added to each well as both feeder and stimulator cells to a total volume of 100 l. Cultures were fed on days 4 and 7 with 50 l of T-cell growth medium and assayed on day 10 or later. The plates were subcultured and maintained in T-cell growth medium and restimulated with gamma-irradiated EW-Ag-876 LCLs. Assays were against either type A or type B LCLs or peptide-coated PHA blasts or LCLs. Precursor frequencies were determined by a modification of the method of maximum likelihood estimation (10) .
Assessment of peptide specific activity. For determination of the antigenic specificity at the peptide level, a set of 20-mer overlapping peptides of EBNA-6B (residues 100 to 1069 [38] ) were prepared by using a kit and software distributed by Chiron Mimotopes (Chiron Corporation, Sydney, Australia). Nine-mer and 10-mer overlapping peptides with unblocked C and N termini were manufacturered by Chiron Mimotopes. Labelled target cells were preincubated with overlapping peptides in the 96-well trays for 30 to 60 min before effectors were added. Alternatively, labelled targets were preincubated with a high concentration of peptide (40 to 80 g/ml) and then washed twice before being used in CTL assays. The washing procedure removes the complication of bystander killing in the latter type of experiments (5).
Depletion experiments. T-cell cultures were depleted of either CD4 ϩ or CD8 
RESULTS

Establishment of T-cell cultures for analysis.
In order to determine the specificity of CTLs from donor patient 1, PBL were isolated and were stimulated by the addition of type A (EW-Wil) or type B (EW-Ag-876) autologous LCLs for 3 days. The cultures were cloned in agarose and colonies were selected, cultured, and assayed for CTL activity toward type A and type B cell lines and the NK target K562. An example of seven reactive cultures is shown in Table 1 . NK reactivity in each case was low (Ͻ10%), and all but one culture (B7) was primarily CD8 positive. All cultures recognized the type B LCL, but three (B4, B5, and B7) were considered to be type B specific, as lytic activity toward type B cells was much greater than that toward type A cells. The remaining cultures showed activity toward both type A and type B targets.
Identification of target antigens. To identify antigens recognized by the CTL cultures, vaccinia virus constructs containing EBV gene sequences (see Materials and Methods) were used to infect autologous type A LCLs (EW-Wil) and used as targets in CTL assays. Three of the cultures (B6, B7, and B9) showed no recognition of any of the gene sequences used. Four cultures (A3, A9, B4, and B5) gave significant enhancement of CTL activity when vacc-EBNA-6B-infected LCLs were compared with control cells or vacc-TK Ϫ -infected target cells and reacted poorly with the other EBV sequences (EBNA-1, EBNA-2B, EBNA-3B, EBNA-4A, LMP1, LMP2, BZLF1, and BHRF1). The specificities of cultures A3 and B5 were investigated further. This was achieved by assaying these cultures with EW-Wil LCLs infected with either vacc-EBNA-6A or vacc-EBNA-6B (Fig. 1) . Culture B5 recognized target cells infected with vacc-EBNA-6B but not with vacc-EBNA-6A.
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This culture also killed autologous type B LCLs (EW-Ag-876) but not type A LCLs (EW-Wil). These results suggested that culture B5 recognized a type B-specific epitope within EBNA-6B. In contrast, the CTL activity of culture A3 against EW-Wil increased following infection by either vacc-EBNA-3A or -3B, indicating that culture A3 recognized a cross-reactive epitope common to both EBNA-6A and EBNA-6B. Recognition of EW-Wil cells infected with vacc-TK Ϫ was as expected, as these target LCLs expressed EBNA-6A.
Characterization of the type B-specific epitope. To determine the minimal amino acid sequence recognized by the type B-specific culture B5, 20-mer peptides, which overlapped by 10 amino acids and encompassed the complete EBNA-6B second exon amino acid sequence, were synthesized. Autologous PHA blasts were preincubated with these peptides and used as targets with culture B5 in CTL assays. This culture recognized the peptide containing the EBNA-6B residues 210 to 229 (FGC QNGALAINTFSATVWIP). To further minimalize this epitope, 9-mer and 10-mer overlapping peptides within this 20-mer sequence were prepared. CTL assays identified the minimal epitope as the 10-mer QNGALAINTF (residues 213 to 222; Fig. 2) . None of the overlapping 9-mer sequences were recognized. The corresponding peptide from the type A overlapping sequence (QNAARTLNTF) was not recognized by this culture (data not shown), thus confirming the type B specificity of these T cells.
Once the minimally active epitope was identified, this peptide was used to sensitize autologous LCLs for rapid identification of subsequent CTL cultures. Of the additional cultures that were type B epitope specific, B15 and B16 were expanded from the limiting dilution assay wells and were studied along with culture B5. HLA restriction of the type B-specific epitope. As FACS assays revealed that cultures recognizing the EBNA-6B-encoded sequence QNGALAINTF consisted of mixtures of CD4 ϩ , CD4 ϩ CD8 ϩ , and CD8 ϩ cells when assayed initially, the possibility that the CTL activity was actually due to a CD4 ϩ component needed to be eliminated. To determine the lytically active cell type, Dynabeads coated with anti-CD4 or anti-CD8 were used to deplete either CD4 ϩ or CD8 ϩ cells from the type B-specific cultures B15 and B16. When samples of three different epitope-reactive cultures were tested, depletion of the CD4 ϩ cells (which would have included the CD4 ϩ CD8 ϩ component) did not reduce the CTL activity, whereas depletion of the CD8 ϩ cells completely abrogated the epitope-specific activity (Fig. 3) . Depletion was confirmed by FACS analysis. Supporting the depletion data, inhibition of type B-specific CTL activity of the mixed cultures was obtained by anti-class I monoclonal antiserum but not by the anti-class II serum (Fig.  4) . These depletion and inhibition experiments thus confirmed that the epitope-specific CTLs were CD8 ϩ class I-restricted T cells.
The restricting allele was identified by sensitizing LCLs, BL cell lines, or PHA blasts, all with known HLA specificities, with the type B epitope and using these as target cells in CTL assays. The only target cells recognized by the QNGALAI NTF-specific CTLs were those that were both HLA A*0201 and B62 (B15) positive. In contrast, targets that expressed HLA A*0201 but not B62 and target cells that only shared A24 or B51 alleles with the donor were not lysed ( Table 2 ). These data indicated that the epitope was B62 (B15) restricted. Characterization of the cross-reactive (type A-B-specific) epitope. Culture A3, which was shown to lyse both type A and type B targets, was assayed against autologous PHA blasts sensitized with pools of overlapping 20-mer peptides derived from the EBNA-6B sequence. Cells sensitized with the pool containing 6 ϫ 20-mer peptides encompassing residues 280 to 349 in EBNA-6B were recognized by this CTL culture. These peptides were subsequently assayed individually, and the peptide corresponding to residues 280 to 299 (TEENLLDFVRF MGVMSSCNS) was identified as the active peptide. Nine-mer and 10-mer overlapping peptides corresponding to this sequence were synthesized and used in CTL assays to minimalize this epitope. The minimally active peptide sequence was identified as LLDFVRFMGV, corresponding to residues 284 to 293 common to both EBNA-6A and -6B sequences. This sequence overlaps with that of the B44-restricted epitope EEN LLDFVRF (residues 281 to 290 of EBNA-6A and -6B [6] ). It should be noted that the minimal epitope for culture A3 was a 10-mer and that the 9-mer peptides were only reactive at high concentrations (data not shown).
HLA restriction of the cross-reactive epitope. HLA restriction analysis of the cross-reactive epitope was performed as described for the type B epitope (Table 2) . Culture A3 consistently recognized cells bearing HLA A*0201 but not cells bearing A24, B51, or B62. Furthermore, the CTL activity of this culture was inhibited by anti-class I antibodies but not by anticlass II antibodies (data not shown). Finally, the A3 minimal epitope corresponds to the motif already identified for HLA A*0201 restriction (32) . It was therefore concluded that the epitope LLDFVRFMGV (corresponding to residues 284 to 293 in both EBNA-6A and EBNA-6B) was HLA class I A*0201 restricted.
Incidence of type B and cross-reactive CTL responses. To attempt to estimate the incidence of type B-specific and crossreactive CTL responses, CTL activity was measured in serially diluted PBL samples stimulated with a feeder layer of irradiated autologous type B LCLs. These were assayed for CTL activity against type A and type B autologous LCLs after 10 days. The results indicated a higher incidence of T-cell precursors recognizing type B cells alone than those recognizing type A and type B cells. Following identification of the minimal peptide sequences for the type B and cross-reactive epitopes, the same cultures were assayed for epitope-specific frequency by limiting dilution analysis. For the type B epitope (QNGA LAINTF), a frequency of 1/16,400 was calculated, compared with 1/304,900 for the cross-reactive epitope (LLDFVRFM GV).
DISCUSSION
The identification of an EBV type B-specific epitope represents the first demonstration of a CTL epitope encoded within a type B-specific region of the EBV genome. The epitope was identified as QNGALAINTF, corresponding to residues 213 to 222 of EBNA-6B. This epitope was shown to be restricted through HLA B62 (B15), although the subtype specificity has yet to be determined. B62, which comprises at least five subtypes, has recently been reclassified as part of the B15 family. Motifs for one member of the B15 family (B*1501) have previously been published (32) . F is commonly found in the last anchor position (9 or 10), and Q or L are the preferred residues at position 2. For the new type B epitope, F is in the anchor position, whereas Q is found at position 1. Interestingly, the corresponding type A sequence for this peptide (QNA ARTLNTF), which was nonreactive in CTL assays (data not shown), also conformed to this motif, suggesting that it may also be able to bind to B*1501. The differences between the type A and type B epitope sequences reside at amino acids 3, 5, 6, and 7 and would be expected to affect CTL recognition, because of T-cell receptor differences, rather than HLA binding, thus explaining the lack of recognition of the type A peptide.
A cross-reactive epitope (LLDFVRFMGV) was also iden- 
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tified. This represents a previously unrecognized EBV-encoded epitope. This epitope corresponds to residues 284 to 293 of both EBNA-6A and -6B and was shown to be restricted through HLA A*0201. This epitope sequence fulfills the published A*0201 motif requirements with L and V as anchor residues at positions 2 and 10 (or positions 2 and 9 in 9-mer epitopes) (reviewed in reference 32). F at position 7 may correspond to F at position 6 in a number of previously identified 9-mer peptides restricted through A*0201. This epitope overlaps with a previously described epitope, EENLLDFVRF, that is B44 restricted (6) . Overlapping epitopes have been described recently within the lytic EBV protein BZLF1 (3) and in other viral systems as well (33, 46) . The occurrence of overlapping epitopes suggests that these regions of the proteins are more likely to be exposed and presented by the major histocompatibility complex, perhaps because of their conformational positions within their respective proteins. An interesting facet of this study was the detection of both type A and type B EBV in the one donor by PCR of both PBL and spontaneous cell lines. Because type A EBV is easy to isolate, it has been thought to predominate in healthy donors. However, the available evidence also indicates a high prevalence of type B in the community (2). It is not known whether this donor was infected with both viruses initially or whether dual infection was the result of initial infection with one type and subsequent infection with the other. If the latter was the case, then it suggests that immunological responses to the first virus type would not be protective against infection with the other virus type.
Mouse model systems have been used to dissect the immune response of host animals infected by more than one virus (reviewed in references 9 and 41). An extrapolation of these models would suggest that eventually one type of EBV would become dominant. It was found in this study that stimulation of the donor's PBL with type A transformants led to the generation of predominantly cross-reactive CTL, while stimulation by type B transformants led to a predominantly type B response (data not shown). The lack of type A-specific CTL may eventually result in dominance of the type A virus in this donor. FIG. 4 . Inhibition of type B-specific epitope recognition by anti-class I antibodies. Cells from EW-C3, a non-cytolytic autologous T-cell culture, were sensitized with type B-specific peptide and used as targets for CTL culture B15 in the presence or absence of antibodies to class I and class II major histocompatibility complex antigens. Finally, it is important when considering the possibility of vaccinating against EBV to recognize that it may be necessary to vaccinate against both type A and type B. If a patient, particularly a transplant patient at risk of EBV-related posttransplant lymphoma (7), is vaccinated against type A but not type B EBV, there may be an even greater risk of clinical disease if the patient is subsequently infected with type B virus. It is particularly important to consider EBV type B epitopes in view of the finding that type B is commonly detected in immunosuppressed individuals. Subunit vaccines against EBV are currently being tested in clinical trials. In the long term, such vaccines would ideally contain cross-protective specificities. Defining type B and cross-reactive epitopes may allow development of a vaccine that is more effective in terms of the range of EBV specificities that are targeted and HLA types that are covered by the vaccine.
